NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS) (NCT00248404) | Clinical Trial Compass
CompletedPhase 1/2
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
United States, Canada155 participantsStarted 2005-09
Plain-language summary
The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Advanced, recurrent, or metastatic solid tumors
* TS overexpression (\> 4 by reverse transcription polymerase chain reaction \[RT-PCR\]) in archival and fresh samples
* Suitable for experimental monotherapy
* Measurable disease
Exclusion Criteria:
* Tumors that cannot be biopsied or with low level of TS expression
* Requirement for concomitant anticancer therapy
* Treatment with another investigational product within 30 days of study entry
* Pregnant or lactating women
* Active or uncontrolled serious bacterial, viral, fungal, or parasitic infection.
* HIV infection
* Clinically apparent meningeal or central nervous system (CNS) metastases or carcinomatous meningitis